Skip to main content

Clinical Trials Using Etoposide

Review the clinical trials studying etoposide on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 51-75 of 85

Antiangiogenic Therapy for Children with Recurrent Medulloblastoma, Ependymoma and ATRT
Status: Active
Location: Medical University of South Carolina, Charleston, South Carolina
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined with BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Combination Chemotherapy in Treating Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) with or without Rituximab plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Pembrolizumab Before and After Autologous Stem Cell Transplant for the Treatment of Relapsed or Refractory Classical Hodgkin Lymphoma
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Epcoritamab with Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Reduced Chemotherapy (N10) for the Treatment of High-Risk Neuroblastoma in Children
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
Chemotherapy with or without Total Body Irradiation before Stem Cell Transplant in Treating Patients with Hodgkin or Non-Hodgkin Lymphoma
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Consolidation Therapy (R-EPOCH) for the Treatment of Patients with Posttransplant Lymphoproliferative Disorder
Status: Active
Location: NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York
Ascorbic Acid and Combination Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, Clonal Cytopenia of Undetermined Significance and Chronic Myelomonocytic Leukemia
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Zanzalintinib in Combination with Oral Etoposide for the Treatment of Relapsed and Refractory Metastatic Germ Cell Tumors
Status: Active
Location: Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana
Total Body Irradiation and Hypofractionated Radiation Therapy with Atezolizumab and Chemotherapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, TESSERACT Trial
Status: Active
Location: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
Mosunetuzumab with Chemotherapy for the Treatment of Patients with Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
Non-Invasive Focused Ultrasound with Oral Etoposide for the Treatment of Children with Progressive/Recurrent Diffuse Midline Glioma
Status: Active
Location: NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
HA-1 T TCR T cell Immunotherapy for the Treatment of Patients with Relapsed or Refractory Acute Leukemia after Donor Stem Cell Transplant
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
A Study of Melphalan in People with Lymphoma Getting an Autologous Hematopoietic Cell Transplant
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
Status: Active
Location: 9 locations
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
Status: Active
Location: See ClinicalTrials.gov